Urine tenascin‑C is an independent risk factor for bladder cancer patients

Guan,Zhenfeng; Zeng,Jin; Wang,Zhiqiang; Xie,Hongjun; Lv,Chuan; Ma,Zhenkun; Xu,Shan; Wang,Xinyang; He,Dalin; Li,Lei

doi:10.3892/mmr.2013.1873

Urine tenascin‑C is an independent risk factor for bladder cancer patients

Authors:
- Zhenfeng Guan
- Jin Zeng
- Zhiqiang Wang
- Hongjun Xie
- Chuan Lv
- Zhenkun Ma
- Shan Xu
- Xinyang Wang
- Dalin He
- Lei Li
View Affiliations

Affiliations: Oncology Research Lab, Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an, Shaanxi, P.R. China, Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China, Department of Urology, The Second People's Hospital of Yinchuan City, Ningxia Hui Autonomous Region, P.R. China
Published online on: December 18, 2013 https://doi.org/10.3892/mmr.2013.1873
Pages: 961-966

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Urine biomarkers offer a non‑invasive method of detecting bladder cancer, monitoring disease progression and predicting disease recurrence and therapeutic treatment efficacy. Tenascin‑C (TN‑C), as a component of the extracellular matrix, is vital in the progression of bladder cancer. However, there is little to report with regard to urine TN‑C and its correlation with bladder cancer grade, stage, recurrence and prognosis. In the present study, 66 samples of voided urine from patients with bladder cancer and 42 samples from volunteers were obtained. The urine TN‑C concentration was determined using an ELISA assay. The correlation between the urine TN‑C concentration and the tumor grade, stage and time from bladder cancer diagnosis to recurrence was analyzed by a rank correlation analysis. Multivariate Cox proportional hazards regression was used for finding the main life‑threatening factors among age, gender, tumor grade, stage, relapse and the urine TN‑C concentration. At the end, the Kaplan‑Meier method was used to evaluate the survival rate affected by urine TN‑C as a single factor. The results indicated that the urine TN‑C concentration in the bladder cancer patients was higher compared with the healthy control volunteers (22.5 times higher). Among all the patients, urine TN‑C concentration had a positive correlation with the bladder cancer grade and stage, with correlation coefficients of 0.905 and 0.308, respectively; however, this correlation was negative between urine TN‑C concentration and the time from bladder cancer diagnosis to recurrence. Moreover, the multivariate Cox proportional hazards model analysis indicated that urine TN‑C, like tumor grade and recurrence, may be an independent risk factor for bladder cancer patient survival. However, it is noteworthy that inflammation may affect the concentration of urine TN‑C. The results of the present study indicate that urine TN‑C may be used as a biomarker for monitoring the recurrence of bladder cancer in patients and for predicting its prognosis. However, inflammation of the urinary tract should be excluded first.

View Figures

View References

1	Griffiths TR: Action on Bladder Cancer: Current perspectives in bladder cancer management. Int J Clin Pract. 67:435–448. 2013. View Article : Google Scholar : PubMed/NCBI
2	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Al Hussain TO and Akhtar M: Molecular basis of urinary bladder cancer. Adv Anat Pathol. 20:53–60. 2013.
4	Kausch I and Böhle A: Bladder cancer. II Molecular aspects and diagnosis. Eur Urol. 39:498–506. 2001.PubMed/NCBI
5	Lokeshwar VB, Schroeder GL, Selzer MG, et al: Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer. 95:61–72. 2002. View Article : Google Scholar : PubMed/NCBI
6	Orend G and Chiquet-Ehrismann R: Tenascin-C induced signaling in cancer. Cancer Lett. 244:143–163. 2006. View Article : Google Scholar : PubMed/NCBI
7	Oskarsson T, Acharyya S, Zhang XH, et al: Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 17:867–874. 2011. View Article : Google Scholar : PubMed/NCBI
8	Berndt A, Köllner R, Richter P, et al: A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol. 133:467–475. 2010. View Article : Google Scholar
9	Brunner A, Mayerl C, Tzankov A, et al: Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol. 57:927–931. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M and Malamou-Mitsi V: A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int. 95:655–659. 2005. View Article : Google Scholar : PubMed/NCBI
11	Hancox RA, Allen MD, Holliday DL, et al: Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res. 11:R242009. View Article : Google Scholar
12	Wunderlich H, Berndt A, Anger K, et al: A1 and D domain of tenascin C - New prognostic marker in bladder cancer. J Urology. 179:3152008. View Article : Google Scholar
13	Fischer D, Brown-Lüdi M, Schulthess T and Chiquet-Ehrismann R: Concerted action of tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite outgrowth. J Cel Sci. 110:1513–1522
14	Babjuk M, Oosterlinck W, Sylvester R, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 54:303–314. 2008. View Article : Google Scholar : PubMed/NCBI
15	Goodison S, Rosser CJ and Urquidi V: Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther. 17:71–84. 2013. View Article : Google Scholar : PubMed/NCBI
16	van Rhijn BW, van der Poel HG and van der Kwast TH: Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. 47:736–748. 2005.
17	Jeong S, Park Y, Cho Y, Kim YR and Kim HS: Diagnostic values of urine CYFRA21–1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin Chim Acta. 414:93–100. 2012.
18	Morgan R, Bryan RT, Javed S, et al: Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Eur J Cancer. Feb 21–2013.(Epub ahead of print).
19	Lei T, Zhao X, Jin S, Meng Q, Zhou H and Zhang M: Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis. Clin Genitourin Cancer. 11:56–62. 2013. View Article : Google Scholar : PubMed/NCBI
20	Vrooman OP and Witjes JA: Urinary markers in bladder cancer. Eur Urol. 53:909–916. 2008. View Article : Google Scholar : PubMed/NCBI
21	Vargová V, Pytliak M and Mechírová V: Matrix metalloproteinases. EXS. 103:1–33. 2012.
22	Paron I, Berchtold S, Vörös J, et al: Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One. 6:e216842011. View Article : Google Scholar : PubMed/NCBI
23	Xue Y, Li J, Latijnhouwers MA, et al: Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Br J Urol. 81:844–851. 1998. View Article : Google Scholar : PubMed/NCBI
24	Katenkamp K, Berndt A, Hindermann W, et al: mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J Pathol. 203:771–779. 2004. View Article : Google Scholar : PubMed/NCBI
25	Parekh K, Ramachandran S, Cooper J, Bigner D, Patterson A and Mohanakumar T: Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer. 47:17–29. 2005. View Article : Google Scholar : PubMed/NCBI
26	Pauli C, Stieber P, Schmitt UM, Andratschke M, Hoffmann K and Wollenberg B: The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck. Anticancer Res. 22:3093–3097. 2002.PubMed/NCBI
27	Booth C, Harnden P, Selby PJ and Southgate J: Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol. 198:359–368. 2002. View Article : Google Scholar : PubMed/NCBI
28	Berndt A, Anger K, Richter P, et al: Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. J Cancer Res Clin Oncol. 132:537–546. 2006. View Article : Google Scholar : PubMed/NCBI
29	Richter P, Tost M, Franz M, et al: B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol. 135:1351–1358. 2009. View Article : Google Scholar : PubMed/NCBI